文献速递肝病消化道肿瘤与早癌

超越肝硬化:纯合与杂合α1-抗胰蛋白酶缺乏相关肝病的主要不良肝脏结局

Beyond cirrhosis: Major adverse liver outcomes across homozygous and heterozygous alpha-1 antitrypsin deficiency-associated liver disease.
PubMed 文献 · Hepatology · 2026-08-28

该回顾性队列研究基于退伍军人肝病分析队列(2000–2025),纳入22537例有基因型检测的参与者,评估Pi*MZ、Pi*SZ和Pi*ZZ基因型相较野生型Pi*MM的主要不良肝脏结局(MALO)风险。结果显示MALO风险随等位基因负荷增加而递增,Pi*MZ、Pi*SZ和Pi*ZZ的aHR分别为1.25、1.51和1.80;Pi*ZZ与所有MALO组分风险显著增加相关,而Pi*SZ和Pi*MZ与失代偿、肝移植和肝病死亡风险升高相关,但与HCC无关。

要点

  • Pi*MZ、Pi*SZ和Pi*ZZ的MALO风险依次递增,aHR分别为1.25、1.51和1.80。
  • Pi*ZZ与失代偿、HCC、肝移植和肝病死亡风险均显著增加相关。
  • Pi*SZ和Pi*MZ与失代偿、肝移植和肝病死亡风险升高相关,但与HCC无关。

核心结论

  • 在拥有AATD基因型检测记录的退伍军人纵向队列中,纯合和杂合Z等位基因携带者均观察到MALO风险增加,提示对已知AATD基因型者需及时诊断和加强临床监测。

研究设计与样本

  • 回顾性队列研究,利用退伍军人肝病分析队列(2000年1月至2025年4月),纳入22537例有基因型检测的参与者,随访352612人年,中位随访15.9年。
  • 基因型通过经验证的自然语言处理识别(κ=0.89),采用多变量Fine-Gray模型估计MALO风险。

主要发现

  • Pi*MM、Pi*MZ、Pi*SZ和Pi*ZZ的MALO发病率分别为每1000人年11.3、13.0、14.6和19.2例;5年MALO概率分别为3.5%、5.5%、5.3%和8.1%。
  • Pi*ZZ与所有个体MALO组分(失代偿、HCC、肝移植和肝病死亡)风险显著增加相关;Pi*SZ和Pi*MZ与失代偿、肝移植和肝病死亡风险升高相关,但与HCC无关。
  • 限制于MASLD参与者的敏感性分析显示一致结果。

临床怎么用

  • 对已知AATD基因型(包括杂合Z等位基因携带者)的退伍军人,应考虑加强肝病监测以及时发现MALO。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Alpha-1 antitrypsin deficiency (AATD) may cause chronic lung and liver disease, yet data on major adverse liver outcomes (MALO) across heterozygous and homozygous Z allele genotypes remain limited. We assessed the risk of MALO across AATD Pi*MZ, Pi*SZ, and Pi*ZZ genotypes compared with the wildtype Pi*MM. APPROACH AND RESULTS: This retrospective cohort study utilized the Veterans Analysis of Liver Disease cohort (January 2000-April 2025). Genotypes were identified using validated natural language processing (κ=0.89). Multivariable Fine-Gray models estimated the hazard of MALO. Among 22,537 participants with genotype testing (19,665 Pi*MM, 1656 Pi*MZ, 281 Pi*SZ, and 935 Pi*ZZ) and 352,612 person-years of follow-up, MALO risk increased sequentially with allele burden: Pi*MZ (aHR 1.25, 1.11-1.40), Pi*SZ (aHR 1.51, 1.17-1.94), and Pi*ZZ (aHR 1.80, 1.57-2.07), versus Pi*MM. MALO incidence rates for Pi*MM, Pi*MZ, Pi*SZ, and Pi*ZZ were 11.3, 13.0, 14.6, and 19.2 per 1000 person-years, respectively, while 5-year MALO probability was 3.5%, 5.5%, 5.3%, and 8.1%, respectively. Pi*ZZ was associated with significantly increased risk of all individual MALO components: decompensation, HCC, liver transplantation (LT), and liver-related death (LRD). Pi*SZ and Pi*MZ were associated with a higher risk of decompensation, LT, and LRD, but not HCC. A sensitivity analysis restricted to participants with MASLD showed consistent findings. CONCLUSION: In this national longitudinal cohort of veterans with documented AATD genotype testing and a median follow-up of 15.9 years, we observed an increased risk of MALO in both homozygous and heterozygous Z-allele carriers, underscoring the need for timely diagnosis and enhanced clinical surveillance among veterans with known AATD genotypes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Bastaich D, Dahman B, Hentschel A, et al. Beyond cirrhosis: Major adverse liver outcomes across homozygous and heterozygous alpha-1 antitrypsin deficiency-associated liver disease. Hepatology. 2026. PMID: 42664383. doi:10.1097/HEP.0000000000001854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。